Inclusion Criteria:  Age ≥18 years old and ≤75 years old; Clinically diagnosed as hepatocellular carcinoma, stage B/C of BCLC; No history of severe arrhythmia or heart failure; No history of severe ventilation dysfunction or severe pulmonary infection; No acute or chronic renal failure, the creatinine clearance rate was >40 mL/min; Liver function Child A; Blood routine: absolute neutrophils count ≥1.5×10^9/L, Hb≥8.5g/L, PLT≥75×10^9/L; Coagulation function: INR≤2.3; ECOG score <2; No local or systemic treatment, such as TACE, RFA, targeted drugs, traditional Chinese medicine, etc., before enrollment; Expected survival ≥12 weeks; At least one lesion can be measured and evaluated by CT/MRI according to RECIST 1.1 criteria; Understand and sign the informed consent.  Exclusion Criteria:  Pregnant or lactating women; Patients with other malignant tumors; patients with complicated mental illness; patients who have participated in other clinical trials in the last three months; known or suspected allergy to any drug related to the study; Patients with positive immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) Patients treated with other targeted drugs, PD-L1 antibody and other immunotherapy or FOLFOX systemic chemotherapy after inclusion; Patients with ≥1 + proteinuria indicated by urine routine will receive 24-hour urine protein detection, and patients with ≥1g 24-hour urine protein will not be included in the group. Active autoimmune diseases that require systemic treatment (use of disease-alleviating agents, such as corticosteroids or immunosuppressants) Patients with uncontrolled hepatitis B/C infection Other conditions that the researcher considers not suitable for inclusion in this study